EVOK has 36-month beta value of 0.34. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EVOK is 6.94M, and currently, short sellers hold a 0.55% ratio of that float. The average trading volume of EVOK on May 24, 2024 was 32.06K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
EVOK) stock’s latest price update
Evoke Pharma Inc (NASDAQ: EVOK)’s stock price has soared by 3.10 in relation to previous closing price of 0.45. Nevertheless, the company has seen a loss of -1.04% in its stock price over the last five trading days. globenewswire.com reported 2024-05-16 that SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its abstract demonstrating enhanced gastroparesis care in women using nasal metoclopramide will be presented at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 2024 in Washington D.C.
EVOK’s Market Performance
Evoke Pharma Inc (EVOK) has experienced a -1.04% fall in stock performance for the past week, with a 3.91% rise in the past month, and a -27.47% drop in the past quarter. The volatility ratio for the week is 14.47%, and the volatility levels for the past 30 days are at 12.99% for EVOK. The simple moving average for the last 20 days is 0.33% for EVOK’s stock, with a simple moving average of -49.64% for the last 200 days.
Analysts’ Opinion of EVOK
Many brokerage firms have already submitted their reports for EVOK stocks, with H.C. Wainwright repeating the rating for EVOK by listing it as a “Buy.” The predicted price for EVOK in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on June 22, 2020 of the previous year 2020.
B. Riley FBR Inc. gave a rating of “Buy” to EVOK, setting the target price at $5 in the report published on March 08th of the previous year.
EVOK Trading at -11.02% from the 50-Day Moving Average
After a stumble in the market that brought EVOK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.45% of loss for the given period.
Volatility was left at 12.99%, however, over the last 30 days, the volatility rate increased by 14.47%, as shares surge +6.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.46% lower at present.
During the last 5 trading sessions, EVOK fell by -1.04%, which changed the moving average for the period of 200-days by -67.02% in comparison to the 20-day moving average, which settled at $0.4649. In addition, Evoke Pharma Inc saw -55.73% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for EVOK
Current profitability levels for the company are sitting at:
- -1.11 for the present operating margin
- 0.96 for the gross margin
The net margin for Evoke Pharma Inc stands at -1.17. The total capital return value is set at -1.94. Equity return is now at value -253.55, with -63.39 for asset returns.
Based on Evoke Pharma Inc (EVOK), the company’s capital structure generated 0.59 points at debt to capital in total, while cash flow to debt ratio is standing at -1.19. The debt to equity ratio resting at 1.43. The interest coverage ratio of the stock is -13.52.
Currently, EBITDA for the company is -7.43 million with net debt to EBITDA at 0.7. When we switch over and look at the enterprise to sales, we see a ratio of -0.12. The receivables turnover for the company is 4.21for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.39.
Conclusion
To put it simply, Evoke Pharma Inc (EVOK) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
